VSTM Latest Press Releases

-- October 22, 2026 --

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026 Business Wire 7:30 AM

-- October 14, 2026 --

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Business Wire 6:04 AM

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan Business Wire 6:01 AM

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) Business Wire 6:00 AM

-- October 5, 2026 --

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- October 2, 2026 --

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 Business Wire 7:30 AM

-- September 29, 2026 --

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer Business Wire 8:06 AM

-- September 24, 2026 --

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting Business Wire 8:30 AM

-- September 8, 2026 --

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers Business Wire 7:30 AM

-- September 2, 2026 --

Verastem Oncology to Participate in Upcoming September Investor Conferences Business Wire 7:30 AM

-- August 6, 2026 --

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates Business Wire 4:01 PM

-- July 28, 2026 --

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer Business Wire 4:01 PM

-- July 23, 2026 --

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire 7:30 AM

-- July 22, 2026 --

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer Business Wire 4:01 PM

-- July 2, 2026 --

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- June 23, 2026 --

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors Business Wire 4:01 PM

-- June 17, 2026 --

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer Business Wire 7:30 AM

-- June 16, 2026 --

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer Business Wire 4:01 PM

-- June 15, 2026 --

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program Business Wire 4:01 PM

-- June 3, 2026 --

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Business Wire 4:01 PM

Market Data Delayed 15 Minutes